Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Colorectal Neoplasms 12Pancreatic Neoplasms 6Cholangiocarcinoma 4Cirrhosis, Familial, with Pulmonary Hypertension 3Esophageal Neoplasms 2Biliary Tract Neoplasms 2Stomach Neoplasms 1Pathologic Complete Response 1Pancreatic Cancer Resectable 1PDAC - Pancreatic Ductal Adenocarcinoma 1Neoplasms, Second Primary 1Neoplasm, Residual 1Neoplasm Metastasis 1Locally Advanced Low Rectal Adenocarcinoma 1Liver Neoplasms 1Liver Metastases of Colorectal Cancer 1Gastroesophageal Junction Cancer 1Esophageal Squamous Cell Carcinoma 1Efficacy and Safety 1Colonic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Neuroendocrine 1CRC 1Biliary Cancer Metastatic 1Appendiceal Neoplasms 1Adenocarcinoma Of Esophagus 1Adenocarcinoma 1

Interventions

irinotecan sucrosofate 1Tegafur 1S 1 (combination) 1Oxaliplatin 1Leucovorin 1Fluorouracil 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Efficacy and Safety × Leucovorin × Clear all
NCT06383078 2024-04-25

HR070803 in Combination With Oxaliplatin, S-1 Versus NALIRIFOX as Adjuvant Therapy for Pancreatic Cancer

The First Affiliated Hospital with Nanjing Medical University

Phase 2 Not yet recruiting
120 enrolled

Efficacy and Safety

Data powered by HemOnc (CC BY 4.0) Colophon âš¡